Dendritic cell-based immunotherapy in multiple myeloma

Leukemia and Lymphoma

Volumn 44, Issue 12, 2003, Pages 2031-2038

  Yi, Qing ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Dendritic cells; Immunotherapy; Multiple myeloma; T cells; Tumor antigens

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; SPERM ANTIGEN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CROSS RESISTANCE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; REVIEW; SOLID TUMOR; TUMOR IMMUNITY; TUMOR MODEL; TUMOR REGRESSION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; T-LYMPHOCYTES; TIME FACTORS;

EID: 0242467305     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000116599     Document Type: Review

References (76)

1. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D. and Crowley, J. (1999) "Total therapy with tandem transplants for newly diagnosed multiple myeloma", Blood 93, 55-65.
2. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughessy, J., Fassas, A., Lim, S., Roberson, P. and Crowley, J. (2000) "Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities", Blood 95, 4008-4010.
3. Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996) "Graft-versus-myeloma effect: proof of principle", Blood 87, 1196-1198.
4. Verdonck, L.F., Lokhorst, H.M., Dekker, A.W., Nieuwenhuis, H.K. and Petersen, E.J. (1996) "Graft-versus-myeloma effect in two cases", Lancet 347, 800-801.
5. Lynch, R.G., Graff, R.J., Sirisinba, S., Simms, E.S. and Eisen, H.N. (1974) "Myeloma proteins as tumor-specific transplantation antigens", Proc. Natl Acad. Sci. USA 69, 1540-1544.
6. Tao, M.H. and Levy, R. (1993) "Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma", Nature 362, 755-758.
7. Sirisinha, S. and Eisen, H.N. (1971) "Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins", Proc. Natl Acad. Sci. USA 68, 3130-3135.
8. Stevenson, F.K. and Gordon, J. (1983) "Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attach by modulation", J. Immunol. 130, 970-973.
9. Kaminski, M.S., Kitamura, K., Maloney, D.G. and Levy, R. (1987) "Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein", J. Immunol. 138, 1289-1296.
10. Campbell, M.J., Esserman, L., Byars, N.E., Allison, A.C. and Levy, R. (1990) "Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity", J. Immunol. 145, 1029-1036.
11. Yi, Q., Bergenbrant, S., Österborg, A., Ösby, E., Östman, R., Björkholm, M., Holm, G. and Lefvert, A.K. (1993) "T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies", Scand. J. Immunol. 38, 529-534.
12. Österborg, A., Yi, Q., Bergenbrant, S., Holm, G., Lefvert, A.K. and Mellstedt, H. (1995) "Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests", Br. J. Haematol. 89, 110-116.
13. Wen, Y.J., Ling, M. and Lim, S.H. (1998) "Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma", Br. J. Haematol. 100, 464-468.
14. Fagerberg, J., Yi, Q., Gigliotti, D., Harmenberg, U., Ruden, U., Persson, B., Österborg, A. and Mellstedt, H. (1999) "T cell epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma", Int. J. Cancer 80, 671-680.
15. + subsets", Br. J. Haematol. 96, 338-345.
16. Yi, Q., Österborg, A., Bergenbrant, S., Mellstedt, H., Holm, G. and Lefvert, A.K. (1995) "Idiotype-reactive T subsets and tumor load in monoclonal gammopathies", Blood 86, 3043-3049.
17. - T cells is associated with the humoral immunodeficiency in myeloma patients", Clin. Exp. Immunol. 109, 310-316.
18. Frassanito, M.A., Cusmai, A. and Dammacco, F. (2001) "Deregulated cytokine network and defective Th1 immune response in multiple myeloma", Clin. Exp. Immunol. 125, 190-197.
19. Wen, Y.J., Barlogie, B. and Yi, Q. (2001) "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells", Blood 97, 1750-1755.
20. + T cells", Blood 96, 2828-2833.
21. Wen, Y.J., Min, R., Tricot, G., Barlogie, B. and Yi, Q. (2002) "Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy", Blood 99, 3280-3285.
22. Dhodapkar, M.V., Krasovsky, J. and Olson, K. (2002) "T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells", Proc. Natl Acad. Sci. USA 99, 13009-13013.
23. Milazzo, C., Reichardt, V.L., Miller, M.R., Grunebach, F. and Brossart, P. (2003) "Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA", Blood 101, 977-982.
24. van Baren, N., Brasseur, F., Godelaine, D., Hames, G., Ferrant, A., Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G.C., Bakkus, M., Thielemans, K. and Boon, T. (1999) "Genes encoding tumor-specific antigens are expressed in human myeloma cells", Blood 94, 1156-1164.
25. Pellat-Deceunynck, C., Mellerin, M.P., Labarriere, N., Jego, G., Moreau-Aubry, A., Harousseau, J.L., Jotereau, F. and Bataille, R. (2000) "The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells", Eur. J. Immunol. 30, 803-809.
26. Gupta, S.K., Shaughnessy, J., Droojenbroeck, J.V., Szmania, S.M., Zhan, F., Batchu, R.B., Spagnoli, G.C., Tricot, G., Pei, L. and van Rhee, F. (2002) "NY-ESO-1 RNA and protein expression in multiple myeloma is highest in aggressive myeloma and is correlated with chromosomal abnormalities [abstract]", Blood 100, 401a.
27. Gupta, S.K., Pei, L., Droojenbroeck, J.V., Szmania, S.M., Yacobby, S., Batchu, R.B., Spagnoli, G.C., Tricot, G., Epstein, J. and van Rhee, F. (2002) "Intra- and intertumoral variation in the expression of cancer testis antigens, MAGE-3 and NY-ESO-1 in multiple myeloma [abstract]", Blood 100, 603a.
28. Szmania, S.M., Bennett, G., Butchu, R.B., Rosen, N.A., Gupta, S.K., Xie, J., Fox, M., Barlogie, B., Tricot, G., Yi, Q. and van Rhee, F. (2002) "Dendritic cells pulsed with NY-ESO-1 and MAGE-3 peptide stimulate myeloma cytotoxic T lymphocytes [abstract]", Blood 100, 399a.
29. Treon, S.P., Mollick, J.A., Urashima, M., Teoh, G., Chauhan, D., Ogata, A., Raje, N., Hilgers, J.H., Nadler, L., Belch, A.R., Pilarski, L.M. and Anderson, K.C. (1999) "Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone", Blood 93, 1287-1298.
30. Lim, S.H., Wang, Z., Chiriva-Internati, M. and Xue, Y. (2001) "Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma", Blood 97, 1508-1510.
31. Ohtomo, T., Sugamata, Y., Ozaki, Y., Ono, K., Yoshimura, Y., Kawai, S., Koishihara, Y., Ozaki, S., Kosaka, M., Hirano, T. and Tsuchiya, M. (1999) "Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells", Biochem. Biophys. Res. Commun. 258, 583-591.
32. Noto, H., Takahashi, T., Makiguchi, Y., Hayashi, T., Hinoda, Y. and Imai, K. (1997) "Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognized an underglycosylated form of MUC1 mucin", Int. Immunol. 9, 791-798.
33. Chiriva-Internati, M., Wang, Z., Salati, E., Bumm, K., Barlogie, B. and Lim, S.H. (2002) "Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma", Blood 100, 961-965.
34. Lim, S.H., Chiriva-Internati, M., Wang, Z. and Salati, E. (2002) "Sperm protein 17 (Sp17) as a tumor vaccine for multiple myeloma [abstract]", Blood 100, 673a.
35. Lacy, H.M. and Sanderson, R.D. (2001) "Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion", Blood 98, 2160-2165.
36. Steinman, R.M. and Cohn, Z.A. (1973) "Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution", J. Exp. Med. 137, 1142-1162.
37. Steinman, R.M. (1991) "The dendritic cell system and its role in immunogenicity", Ann. Rev. Immunol. 9, 271-296.
38. Banchereau, J. and Steinman, R.M. (1988) "Dendritic cells and the control of immunity", Nature 392, 245-252.
39. Grabbe, S., Beissert, S., Schwartz, T. and Granstein, R.D. (1995) "Dendritic cells as initiators of tumor immune response: a possible strategy for tumor immunotherapy?", Immunol. Today 16, 117-121.
40. Girolomoni, G. and Ricciardi-Castagnoli, P. (1997) "Dendritic cells hold promise for immunotherapy", Immunol. Today 118, 102-104.
41. + progenitors in human bone marrow", J. Immunol. 149, 2681-2688.
42. Sallusto, F. and Lanzavecchia, A. (1994) "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α", J. Exp. Med. 179, 1109-1118.
43. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P.O., Steinman, R.M. and Schuler, G. (1994) "Proliferating dendritic cell progenitors in human blood", J. Exp. Med. 180, 83-93.
44. Shimizu, J., Suda, T., Yoshioka, T., Kosugi, A., Fujiwara, H. and Hamaoka, T. (1989) "Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells", J. Immunol. 142, 1053-1059.
45. Grabbe, S., Bruvers, S., Gallo, R.L., Knisely, T.L., Nazareno, R. and Granstein, R.D. (1991) "Tumor antigen presentation by murine epidermal cells", J. Immunol. 146, 3656-3661.
46. Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Tielemans, R, Leo, O., Urbain, J. and Moser, M. (1994) "Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo", Eur. J. Immunol. 24, 605-610.
47. Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Casare, C.M., Appasamy, P.M., Lotze, M.T., Storkus, W.J., Appella, E. and DeLeo, A.B. (1996) "Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines", J. Exp. Med. 183, 1357-1365.
48. Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi, B., Engleman, E.G. and Levy, R. (1996) "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells", Nat. Med. 4, 52-58.
49. Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", Nat. Med. 4, 328-332.
50. Dabadghao, S., Bergenbrant, S., Anton, D., He, W., Holm, G. and Yi, Q. (1998) "Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells", Br. J. Haematol. 100, 647-654.
51. Butch, A.W., Kelly, K.A. and Munshi, N.C. (2001) "Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein", Exp. Hematol. 29, 85-92.
52. Ratta, M., Curti, A., Fogli, M., Pantucci, M., Viscomi, G., Tazzari, P., Fagnoni, F., Vescovini, R., Sansoni, P., Tura, S. and Lemoli, L.M. (2000) "Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients", Exp. Hematol. 28, 931-940.
53. Demic, Z., Schenck, K. and Bogen, B. (2000) "Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells", Proc. Natl Acad. Sci. USA 97, 2697-2702.
54. Wen, Y.J., Ling, M., Bailey-Wood, R. and Lim, S.H. (1998) "Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma", Clin. Cancer Res. 4, 957-962.
55. Lim, S.H. and Bailey-Wood, R. (1999) "Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma", Int. J. Cancer 83, 215-222.
56. Reichardt, V.L., Okada, C.Y, Liso, A., Beike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume, K.G. and Levy, R. (1999) "Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study", Blood 93, 2411-2419.
57. Liso, A., Stockerl-Goldstein, K.E., Auffermann-Gretzinger, S., Beike, C.J., Reichardt, V.L., van Beckhoven, A., Rajapaksa, R., Engleman, E.G., Blume, K.G. and Levy, R. (2000) "Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma", Biol. Blood Marrow Transplant. 6, 621-627.
58. Cull, G., Durrant, L., Stainer, C., Haynes, A. and Russell, N. (1999) "Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma", Br. J. Haematol. 107, 648-655.
59. Titzer, S., Christensen, O., Manzke, O., Tesch, H., Wolf, J., Emmerich, B., Carsten, C., Diehl, V. and Bohlen, H. (2000) "Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects", Br. J. Haematol. 108, 805-816.
60. Lacy, M.Q., Geyer, S., Wettstein, P., Gertz, M.A., Gastineau, D.A., Greipp, P.R., Fonseca, R., Dispenzieri, A., Lust, J.A., Witzig, T.E., Rajkumar, S.V., Zeldenrust, S., Maas, M., Iturria, N., Weiden, P. and Kyle, R.A. (2002) "Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (dendritic) cells (APC8020) is associated with a trend to longer time to progression [abstract]", Blood 100, 425a.
61. Eggert, A.A., Schreurs, M.W., Boerman, O.C., Oyen, W.J., de Boer, A.J., Punt, C.J., Figdor, C.G. and Adema, G.J. (1999) "Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration", Cancer Res. 59, 3340-3345.
62. Morse, M.A., Coleman, R.E., Akabani, G., Niehaus, N., Coleman, D. and Lyerly, H.K. (1999) "Migration of human dendritic cells after injection in patients with metastatic malignancies", Cancer Res. 59, 56-58.
63. Fong, L., Brockstedt, D., Benike, C., Wu, L. and Engleman, E.G. (2001) "Dendritic cells injected via different routes induce immunity in cancer patients", J. Immunol. 166, 4254-4259.
64. Palucka, K.A., Taquet, N., Sanchez-Chapuis, F. and Gluckman, J.C. (1998) "Dendritic cells as the terminal stage of monocyte differentiation", J. Immunol. 160, 4587-4595.
65. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells", J. Exp. Med. 192, 1213-1222.
66. Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Manz, C. and Bhardwaj, N. (2001) "Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells", J. Exp. Med. 193, 233-238.
67. Yi, Q., Desikan, R., Barlogie, B. and Munshi, N. (2002) "Optimising dendritic cell-based immunotherapy in multiple myeloma", Br. J. Haematol. 117, 297-305.
68. Szmania, S.M., Rosen, N.A., Gupta, S.K., Batchu, R.B., Barlogie, B., Cottler-Fox, M., Tricot, G., Yi, Q. and van Rhee, F. (2002) "Robust immune responses to vaccination with autologous myeloma tumor lysate loaded dendritic cells [abstract]", Blood 100, 400a.
69. Gong, J., Chen, D. and Kufe, D. (1997) "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells", Nat. Med. 3, 558-561.
70. Wang, J., Saffold, S., Cao, X., Krauss, J. and Chen, W. (1998) "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", J. Immunol. 161, 5516-5524.
71. Gong, J., Chen, D., Kashiwaba, M., Li, Y., Chen, L., Takeuchi, H., Qu, H., Rowse, G.J., Gendler, S.J. and Kufe, D. (1998) "Reversal of tolerance of human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells", Proc. Natl Acad. Sci. USA 95, 6279-6283.
72. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C.A., Becker, V., Gross, A.J., Hemmerlein, B., Kanz, L., Muller, G.A. and Ringert, R.H. (2000) "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", Nat. Med. 6, 332-336.
73. Gong, J., Koido, S., Chen, D., Tanaka, Y., Huang, L., Avigan, D., Anderson, K., Ohno, T. and Kufe, D. (2002) "Immunization against marine multiple myeloma with fusions of dendritic and plasmacytoma cells potentiated by interleukin 12", Blood 99, 2512-2517.
74. Liu, Y., Zhang, W., Chan, T., Saxena, A. and Xiang, J. (2002) "Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity", Leuk. Res. 26, 757-763.
75. Grosman, D.D., Borges, V., Vasir, D., Wu, Z., Anderson, K., Richardson, P., Munshi, N., Kufe, D. and Avigan, D. (2002) "Dendritic cell (DC)-tumor fusions generated with mature as compared to immature DC potently induced myeloma specific immunity [abstract]", Blood 100, 399a.
76. Yi, Q. (2002) "Immunoregulatory mechanisms and immunotherapy", In: Mehta, J. and Singhal, S., eds, Myeloma (Martin Dunitz, London, UK) pp 81-96.